First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.

Trial Details

NCT ID
NCT06795022
Phase
PHASE1 / PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • AZD9793 Intravenous (IV) monotherapy
  • AZD9793 Subcutaneous (SC) monotherapy
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Los Angeles, California, United States|34.05223,-118.24368
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Age ≥ 18 at the time of signing the informed consent.
  • GPC3 positive tumour as determined by a central laboratory using an analytically validated IHC assay. Patients who previously received any therapy …
  • Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Eastern Cooperative Oncology Group Performance status (ECOG PS): 0-1 at screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →